Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
Original Broadcast Date: Tuesday, July 11, 2017
Opioids are one of the medication classes included in ISMP’s list of high-alert medications, which are drugs that bear a heightened risk of causing significant harm when used in error. Morphine and HYDROmorphone are both commonly used, yet remain among the most frequent opioids to cause patient harm. This webinar will explore the latest trends in opioid therapy, barriers to optimal therapy and safety, and preventable errors that involve opioids. Expert speakers will discuss the latest safety considerations for these commonly-used agents, including a surprising discussion regarding the safe use of HYDROmorphone.
The target audience for this activity includes Nurses, Pharmacists, Clinical educators, Pain teams, Pharmacy and nursing managers and administrators, Medication safety and patient safety officers, Risk and quality managers, and Hospital and health system leadership.
At the completion of this webinar, the participant will be able to:
Introduction and Overview
Michael R. Cohen, RPh, MS, ScD (hon.), DPS (hon.), FASHP – President, ISMP
System-based Causes of Adverse Events Associated with Opioids
Matthew Grissinger, RPh, FISMP, FASCP
Director of Error Reporting Programs, ISMP
Selecting Appropriate Opioid Therapy for Severe or Chronic Pain
Maria Foy, PharmD, BCPS, CPE
Patient Care Coordinator, Palliative Care, Abington Memorial Hospital, Abington, PA
This non-accredited webinar is sponsored by Fresenius Kabi.
|Institute for Safe Medication Practices (ISMP)
200 Lakeside Drive, Suite 200, Horsham, PA 19044
Phone: (215) 947-7797 www.ismp.org
For registration questions, contact ProCE at 1-800-748-7795.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.